Amphotericin B in lipid emulsion: Stability, compatibility, and in vitro antifungal activity

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 4, 1998, Pages 762-766

  Walker, Scott ^a,b   Tailor, Sandra A N ^a,b   Lee, Mark ^a,b   Louie, Lisa ^a   Louie, Marie ^a,b   Simor, Andrew E ^a,b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; INTRALIPID; LIPID EMULSION;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; DRUG STABILITY; DRUG STORAGE; NONHUMAN; PRIORITY JOURNAL; YEAST;

EID: 0031977534     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.4.762     Document Type: Article

References (35)

1. Caillot, D., P. Chavanet, O. Casasnovas, E. Solary, G. Zanetta, M. Buisson, O. Wagner, B. Cuisenier, A. Bonnin, P. Camerlynk, H. Portier, and H. Guy. 1992. Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B. Eur. J. Clin. Microbiol. Infect. Dis. 11: 722-725.
2. Caillot, D., G. Reny, E. Solary, O. Casasnovas, P. Chavanet, B. Bonnotte, L. Perello, M. Dumas, F. Entezam, and H. Guy. 1994. A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. J. Antimicrob. Chemother. 33:603-613.
3. Chavanet, P., N. Charlier, A. Brenet, A. Goux, E. Muggéo, D. Caillot, O. Casasnovas, J. P. Kistermann, A. Waldner, and H. Portier. 1992. Émulsion de l'amphotéricine B dans l'Intralipide 20%: efficacité in vitro et in vivo. Pathol. Biol. 40:507-512.
4. Chavanet, P., I. Garry, N. Charlier, D. Caillot, J. P. Kistermann, M. D'Athis, and H. Portier. 1992. Trial of glucose versus fat emulsion in preparation of amphotericin B for use in HIV infected patients with candidiasis. Br. Med. J. 305:921-925.
5. Davis, S. S., C. Washington, P. West, L. Illum, G. Liversidge, L. Sternson, and R. Kirsh. 1987. Lipid emulsions as drug delivery systems. Ann. N. Y. Acad. Sci. 507:75-88.
6. de Marie, S., R. Janknegt, and I. A. J. M. Bakker-Woudenberg. 1994. Clinical use of liposomal and lipid-complexed amphotericin B. J. Antimicrob. Chemother. 33:907-916.
7. Ericsson, O., A. Hallmen, and I. Wikstrom. 1996. Amphotericin B is incompatible with lipid emulsions. Ann. Pharmacother. 30:298.
8. Gross, M. H., W. W. Pickard, and J. R. Perfect. 1987. Retrospective review of amphotericin B use in a tertiary-care medical center. Am. J. Hosp. Pharm. 44:1353-1357.
9. Heide, P. E. 1997. Precipitation of amphotericin B from iv fat emulsion. Am. J. Health-Syst. Pharm. 54:1449.
10. Heinemann, V., B. Kähny, U. Jehn, D. Mühlbayer, A. Debus, K. Wachholz, D. Bosse, H.-J. Kolb, and W. Wilmanns. 1997. Serum pharmacology of amphotericin B applied in lipid emulsions. Antimicrob. Agents Chemother. 41:723-732.
11. Herbrecht, R., and V. Letscher. 1997. Safety and efficacy of Intralipid emulsions of amphotericin B. J. Antimicrob. Chemother. 40:137-139.
12. Janknegt, R., S. de Marie, I. A. J. M. Bakker-Woudenberg, and D. J.-A. Crommelin. 1992. Liposomal and lipid formulations of amphotericin B. Clin. Pharmacokinet. 23:279-291.
13. Joly, V., R. Farinotti, L. Saint-Julien, M. Chéron, C. Carbon, and P. Yeni. 1994. In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid. Antimicrob. Agents Chemother. 38:1771-1783.
14. Kan, V. L., J. E. Bennett, M. A. Amantea, M. C. Smolskis, E. McManus, D. M. Grasela, and J. W. Sherman. 1991. Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers. J. Infect. Dis. 164:418-421.
15. Khoo, S. H., J. Bond, and D. W. Denning. 1994. Administering amphotericin B - a practical approach. J. Antimicrob. Chemother. 33:203-213.
16. Kintzel, P. E. 1996. Amphotericin B in fat emulsion. Am. J. Health-Syst. Pharm. 53:2701.
17. Kirsh, R., R. Goldstein, J. Tarloff, D. Paris, J. Hook, N. Hanna, P. Bugelski, and G. Poste. 1988. An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J. Infect. Dis. 158:1065-1070.
18. Lee, M. D., M. M. Hess, B. A. Boucher, and A. M. Apple. 1994. Stability of amphotericin B in 5% dextrose injection stored at 4° or 25°C for 120 hours. Am. J. Hosp. Pharm. 51:394-396.
19. Lopez, R. M., A. Ayestaran, L. Pou, J. B. Montoro, M. Hernandez, and I. Caragol. 1996. Stability of amphotericin B in an extemporaneously prepared i.v. fat emulsion. Am. J. Health-Syst. Pharm. 53:2724-2727.
20. Lopez-Berestein, G., V. Fainstein, R. Hopfer, K. Mehta, M. P. Sullivan, M. Keating, M. G. Rosenblum, R. Mehta, M. Luna, E. M. Hersh, J. Reuben, R. L. Juliano, and G. P. Bodey. 1985. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J. Infect. Dis. 151:704-710.
21. Maddux, M. S., and S. L. Barriere. 1980. A review of complications of amphotericin B therapy: recommendations for prevention and management. Drug Intell. Clin. Pharm. 14:177-181.
22. Meunier, F. 1989. New methods for delivery of antifungal agents. Rev. Infect. Dis. 11:51605-81612.
23. Moreau, P., N. Milpied, N. Fayette, J. F. Ramee, and J. L. Harousseau. 1992. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with Intralipid compared with conventional amphotericin B in neutropenic patients. J. Antimicrob. Chemother. 30:535-541.
24. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
25. Oldfield, E. C., III, P. D. Garst, C. Hostettler, M. White, and D. Samuelson. 1990. Randomized, double-blind trial of 1-versus 4-hour amphotericin B infusion durations. Antimicrob. Agents Chemother. 34:1402-1406.
26. Owens, D., R. A. Fleming, M. S. Restino, J. M. Cruz, and D. D. Hurd. 1997. Stability of amphotericin B 0.05 and 0.5 mg/ml in 20% fat emulsion. Am. J. Health-Syst. Pharm. 54:683-686.
27. Ranchere, J. Y., J. F. Latour, C. Furhmann, C. Lagallarde, and F. Loreuil. 1996. Amphotericin B intralipid formulation: stability and particle size. J. Antimicrob. Chemother. 37:1165-1169.
28. Salama, S., and C. Rotstein. 1997. Reduction in the nephrotoxicity of amphotericin B when administered in 20% intralipid. Can. J. Infect. Dis. 8:157-160.
29. Sievers, T. M., B. M. Kubak, and A. Wong-Beringer. 1996. Safety and efficacy of Intralipid emulsions of amphotericin B. J. Antimicrob. Chemother. 38: 333-347.
30. Sorkine, P., H. Nagar, A. Weinbroum, A. Setton, E. Israitel, A. Scarlatt, A. Silbiger, V. Rudick, V. Kluger, and P. Halpern. 1996. Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective randomized, controlled study in critically ill patients. Crit. Care Med. 24:1311-1315.
31. Trissel, L. A. 1983. Avoiding common flaws in stability and compatibility studies of injectable drugs. Am. J. Hosp. Pharm. 40:1159-1160.
32. Trissel, L. A. 1995. Amphotericin B does not mix with fat emulsion. Am. J. Health-Syst. Pharm. 52:1463-1464. (Letter.)
33. Trissel, L. A., and K. P. Flora. 1988. Stability studies: five years later. Am. J. Hosp. Pharm. 45:1569-1571.
34. Washington, C., M. Lance, and S. S. Davis. 1993. Toxicity of amphotericin B emulsion formulations. J. Antimicrob. Chemother. 31:806-808.
35. Wiebe, V. J., and M. W. DeGregario. 1988. Liposome-encapsulated amphotericin B: a promising new treatment for disseminated fungal infections. Rev. Infect. Dis. 10:1097-1101.